Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical tria...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Neurol
Autors principals: Moccia, Marcello, Lanzillo, Roberta, Petruzzo, Martina, Nozzolillo, Agostino, De Angelis, Marcello, Carotenuto, Antonio, Palladino, Raffaele, Brescia Morra, Vincenzo
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7311570/
https://ncbi.nlm.nih.gov/pubmed/32625161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00489
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars